Name: AAL-993
Price: 231.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 130, 23, and 18 nM for VEGFR1, 2, and 3, respectively
    AAL-993 is a VEGF receptor inhibitor.
    A key pro-angiogenic cytokine released by tumor is vascular endothelial growth factor (VEGF). The angiogenic activity of the VEGF family of proteins is mediated by two high affinity receptors, VEGFR-1 and VEGFR-2 located on vascular endothelial cells.
    In vitro: AAL-993 was found to be a highly potent and selective inhibitor of the recombinant VEGFR-2 and VEGFR-3 kinases. At 3- to 5-fold higher concentration, AAL-993 also inhibited VEGFR-1 and, although it possessed some activity against other members of the PDGFR kinase family at submicromolar concentrations, AAL-993 did not significantly inhibit any of the other kinases tested at concentrations
    In vivo: Animal efficacy study found that AAL-993 was able to potently inhibit VEGF-induced angiogenesis in an implant model, with ED50 values of 7 mg/kg. Moreover, in a mouse orthotopic model of melanoma, AAL-993 could potently inhibit both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases [1].
    Clinical trial: So far, no clinical study has been conducted.
- Properties
  - Alternative Name
    
    VEGFR Tyrosine Kinase Inhibitor VI,ZK 260253; 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-benzamide
    
    CAS Number
    
    269390-77-4
    
    Molecular Formula
    
    C20H16F3N3O
    
    Molecular Weight
    
    371.4
    
    Appearance
    
    A crystalline solid
    
    Purity
    
    Purity ≥95.00%
    
    Solubility
    
    ≤1mg/ml in ethanol;25mg/ml in DMSO;30mg/ml in dimethyl formamide
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only